FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Laurence Rimsky

Research Profile

Living Beings

Chemicals & Drugs

Concepts & Ideas

Anatomy

Physiology

Disorders

HIV Infections

Genes & Molecular Sequences

Amino Acid Sequences

Co-author Network

Publications

TOP 3
Johan Vingerhoets; Katia Boven; Steven Nijs; Laurence Rimsky; Veerle Van Eygen; Simon Vanveggel; Gaston Picchio
Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.
Calvin J Cohen; Herta Crauwels; Jan Fourie; Beatriz Grinsztejn; Margaret A Johnson; Eric Lefebvre; Jean-Michel Molina; Laurence Rimsky; Michael Saag; Khuanchai Supparatpinyo; Simon Vanveggel; Peter Williams; Hao Wu; Katia Boven; Pedro Cahn; Bonaventura Clotet
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
Aimee Wilkin; Katia Boven; Beatriz Grinsztejn; Sergio H Lupo; Javier Morales-Ramirez; Anton L Pozniak; Laurence Rimsky; Kiat Ruxrungtham; Mario Santoscoy; Simon Vanveggel
Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Laurence Rimsky (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Johan Vingerhoets; Katia Boven; Steven Nijs; Laurence Rimsky; Veerle Van Eygen; Simon Vanveggel; Gaston Picchio
Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.
Antiviral therapy 2013;18(2):253-6.
2012: Calvin J Cohen; Herta Crauwels; Jan Fourie; Beatriz Grinsztejn; Margaret A Johnson; Eric Lefebvre; Jean-Michel Molina; Laurence Rimsky; Michael Saag; Khuanchai Supparatpinyo; Simon Vanveggel; Peter Williams; Hao Wu; Katia Boven; Pedro Cahn; Bonaventura Clotet
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
Journal of acquired immune deficiency syndromes (1999) 2012;60(1):33-42.
2012: Aimee Wilkin; Katia Boven; Beatriz Grinsztejn; Sergio H Lupo; Javier Morales-Ramirez; Anton L Pozniak; Laurence Rimsky; Kiat Ruxrungtham; Mario Santoscoy; Simon Vanveggel
Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.
AIDS research and human retroviruses 2012;28(5):437-46.
2012: Laurence Rimsky; Katia Boven; Joseph Eron; Johan Vingerhoets; Bonaventura Clotet; Annemie Hoogstoel; Veerle Van Eygen; Gaston Picchio
Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.
Journal of acquired immune deficiency syndromes (1999) 2012;59(1):39-46.
2012: Rima Kulkarni; Michael D Miller; Veerle Van Eygen; Kerim Babaoglu; Gaston Picchio; Eric B Lansdon; Laurence Rimsky; Evguenia Svarovskaia; Kirsten L White
The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.
Journal of acquired immune deficiency syndromes (1999) 2012;59(1):47-54.
2011: Jean-Michel Molina; Laurence Rimsky; Michael Saag; Khuanchai Supparatpinyo; Simon Vanveggel; Sharon Walmsley; Katia Boven; Pedro Cahn; Herta Crauwels; Beatriz Grinsztejn; Adriano Lazzarin; Anthony Mills
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Lancet 2011;378(9787):238-46.
2011: Calvin J Cohen; Herta Crauwels; Jan Fourie; Margaret A Johnson; Laurence Rimsky; Kiat Ruxrungtham; Simon Vanveggel; Hao Wu; Carmen Zorrilla; Jaime Andrade-Villanueva; Katia Boven; Bonaventura Clotet
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Lancet 2011;378(9787):229-37.
2010: Johan Vingerhoets; Hilde Azijn; Lotke Tambuyzer; Inge Dierynck; Sandra De Meyer; Laurence Rimsky; Steven Nijs; Goedele De Smedt; Marie-Pierre de Bethune; Gaston Picchio
Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.
AIDS research and human retroviruses 2010;26(6):621-4.
2010: Hilde Azijn; Ilse Tirry; Johan Vingerhoets; Marie-Pierre de Bethune; Gunter Kraus; Katia Boven; Dirk Jochmans; Elke Van Craenenbroeck; Gaston Picchio; Laurence Rimsky
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Antimicrobial agents and chemotherapy 2010;54(2):718-27.
2010: Anton L Pozniak; Javier Morales-Ramirez; Elly Katabira; Dewald Steyn; Sergio H Lupo; Mario Santoscoy; Beatriz Grinsztejn; Kiat Ruxrungtham; Laurence Rimsky; Simon Vanveggel; Katia Boven
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.
AIDS (London, England) 2010;24(1):55-65.
2009: Lotke Tambuyzer; Hilde Azijn; Laurence Rimsky; Johan Vingerhoets; Pierre Lecocq; Gunter Kraus; Gaston Picchio; Marie-Pierre de Bethune
Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
Antiviral therapy 2009;14(1):103-9.
2007: Gregory F Guzauskas; Kennedy Ukadike; Laurence Rimsky; Anand K Srivastava
tSNP-based identification of allelic loss of gene expression in a patient with a balanced chromosomal rearrangement.
Genomics 2007;89(4):562-5.
2006: Joy Y Feng; Florence Myrick; Nicolas A Margot; Gilbert B Mulamba; Laurence Rimsky; Katyna Borroto-Esoda; Boulbaba Selmi; Bruno Canard
Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
Nucleosides, nucleotides & nucleic acids 2006;25(1):89-107.
2004: Anne-Carole Jacquard; Michael Nassal; Christian Pichoud; S Ren; Ursula Schultz; Sylviane Guerret; Michèle Chevallier; B Werle; Simone Peyrol; Catherine Jamard; Laurence Rimsky; Christian Trepo; Fabien Zoulim
Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection.
Antimicrobial agents and chemotherapy 2004;48(7):2683-92.
2003: Béatrice Seignères; Perrine Martin; Bettina Werle; Olivier Schorr; Catherine Jamard; Laurence Rimsky; Christian Trépo; Fabien Zoulim
Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model.
Antimicrobial agents and chemotherapy 2003;47(6):1842-52.
1998: Laurence Rimsky; D C Shugars; TJ Matthews
Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides.
Journal of virology 1998;72(2):986-93.
1995: M Girard; B Meignier; Françoise Barré-Sinoussi; Marie Paule Kieny; T Matthews; E Muchmore; P L Nara; Q Wei; Laurence Rimsky; Kent J Weinhold
Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.
Journal of virology 1995;69(10):6239-48.
1991: J H Kim; P A Kaufman; S M Hanly; Laurence Rimsky; Warner Greene
Rex transregulation of human T-cell leukemia virus type II gene expression.
Journal of virology 1991;65(1):405-14.
1990: A Harel-Bellan; P Krief; Laurence Rimsky; W L Farrar; Z Mishal
Flow cytometry resonance energy transfer suggests an association between low-affinity interleukin 2 binding sites and HLA class I molecules.
The Biochemical journal 1990;268(1):35-40.
1989: Laurence Rimsky; M D Dodon; E P Dixon; Warner Greene
Trans-dominant inactivation of HTLV-I and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator.
Nature 1989;341(6241):453-6.
1989: S M Hanly; Laurence Rimsky; Michael H Malim; J H Kim; Joachim Hauber; M Duc Dodon; S Y Le; jacob valentine maizel; Bryan R Cullen; Warner Greene
Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements.
Genes & development 1989;3(10):1534-44.
1989: E Böhnlein; M Siekevitz; Dean W Ballard; J W Lowenthal; Laurence Rimsky; H Bogérd; J Hoffman; Y Wano; B R Franza; Warner Greene
Stimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteins.
Journal of virology 1989;63(4):1578-86.
1989: Jacques Bertoglio; E Wollman; A Shaw; Laurence Rimsky; Didier Fradelizi
Identification of interleukin 1 alpha produced by the 3B6 human EBV-B cell line.
Lymphokine research 1989;8(1):19-24.
1988: E E Wollman; L d'Auriol; Laurence Rimsky; A Shaw; jean-pierre jacquot; P Wingfield; P Graber; F Dessarps; Philippe Robin; F Galibert
Cloning and expression of a cDNA for human thioredoxin.
The Journal of biological chemistry 1988;263(30):15506-12.
1988: Laurence Rimsky; Joachim Hauber; M Dukovich; Michael H Malim; A Langlois; Bryan R Cullen; Warner Greene
Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein.
Nature 1988;335(6192):738-40.
1988: Jacques Bertoglio; E Wollman; Laurence Rimsky; Didier Fradelizi; A Shaw
A novel protein from cloned human B-cell line displays IL-1 bioactivity.
Journal of immunology (Baltimore, Md. : 1950) 1988;141(8):2869-70.
1987: H Wakasugi; C Bensimon; Y Mahé; Pierre Busson; Laurence Rimsky; Didier Fradelizi; Jacques Bertoglio; Thomas Tursz
B-cell-derived interleukin-1.
Annales de l'Institut Pasteur. Immunology 1987;138(4):599-603.
1987: H Wakasugi; Laurence Rimsky; Y Mahe; Azza Kamel; Didier Fradelizi; Thomas Tursz; J Bertoglio
Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(3):804-8.
1987: Jacques Bertoglio; Laurence Rimsky; E S Kleinerman; L B Lachman
B-cell line-derived interleukin 1 is cytotoxic for melanoma cells and promotes the proliferation of an astrocytoma cell line.
Lymphokine research 1987;6(2):83-91.
1986: Laurence Rimsky; H Wakasugi; Pascual Ferrara; Philippe Robin; J Capdevielle; Thomas Tursz; Didier Fradelizi; Jacques Bertoglio
Purification to homogeneity and NH2-terminal amino acid sequence of a novel interleukin 1 species derived from a human B cell line.
Journal of immunology (Baltimore, Md. : 1950) 1986;136(9):3304-10.
1983: V Souvannavong; Laurence Rimsky; A Adam
In vitro immune response to sheep erythrocytes in macrophage depleted cultures. Restoration with interleukine 1 or a monokine from resident macrophages and stimulation by N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP).
Biochemical and biophysical research communications 1983;114(2):721-8.
1983: Laurence Rimsky; V Souvannavong; L Le Bouffant; A Adam
[Secretion of two different monokines. Effect of TPA and silica].
Comptes rendus des séances de l'Académie des sciences. Série III, Sciences de la vie 1983;296(7):329-34.